Get the Stockscreener App
6.08
1.30%
-0.08
After Hours:
6.15
0.07
+1.15%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $6.08, with a volume of 2.55M.
It is down -1.30% in the last 24 hours and down -17.95% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$6.16
Open:
$6.11
24h Volume:
2.55M
Relative Volume:
1.03
Market Cap:
$2.25B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-12.67
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
+7.42%
1M Performance:
-17.95%
6M Performance:
-8.71%
1Y Performance:
-4.55%
1-Day Range:
$5.97
$6.20
1-Week Range:
$5.62
$6.305
52-Week Range:
$4.25
$8.685
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.08 | 2.28B | 9.47B | -178.00M | 1.01B | -0.48 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Idahoans may be eligible for money from generic drug settlement - KMVT
Idaho joins $17.85M settlement over alleged generic drug price-fixing - KTVB
$17.85 Million in Settlements in Ongoing Generic Drug Price-Fixing Conspiracy Cases - Big Country News
Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Bausch + Lomb CEO: Standing still is the new falling behind - Fortune
10 students living with GI disease to get up to $10K for school - Stock Titan
Bausch Health Cos (BHC) to Release Earnings on Wednesday - MarketBeat
AG settlements with Lannett and Bausch $17M - Oregon Business Report
Future of Ion Channel Modulators Market Growth (2026-2033) | - openPR.com
Scar Treatment Market Expected See Incredible Growth - openPR.com
Is Bausch Health (BHC) Pricing Reflect Long Term Potential After 81% Five Year Share Slump - Sahm
Migraine Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | GSK, Merck, Pfizer, Bausch Health, Amgen, Abbvie AstraZeneca, Eli Lilly and Co - Barchart.com
The Truth About Bausch Health Companies: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Lupin’s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch HealthLupin | Press Release - lupin.com
AG Drummond reaches settlement with drug companies accused of price-fixing - fox23.com
The Bull Case For Bausch Health Companies (BHC) Could Change Following Failed Xifaxan RED-C Trials Learn Why - Yahoo Finance
Wall Street Zen Upgrades Bausch Health Cos (NYSE:BHC) to "Strong-Buy" - MarketBeat
Are you eligible to receive a portion of $17 million pharmaceutical settlement? - FourStatesHomepage.com
Bausch Health (BHC) Announces Global Phase 3 RED-C Clinical Program Results - Finviz
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Qiagen (QGEN) and InnovAge Holding (INNV) - The Globe and Mail
CT Prescription Buyers Could See Refunds In $17.9M Drug Price-Fixing Settlement - AOL.com
Quarterly Earnings: Is HGBL in a long term uptrendTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Connecticut AG William Tong settles with Lannett and Bausch for nearly $18 million - fox61.com
Michigan AG Secures $17.85M in Settlements with Lannett, Bausch Over Generic Drug Price-Fixing Allegations - Hoodline
Nebraska Attorney General’s Office Announces Settlements with Lannett and Bausch Totaling $17.85 Million Over Conspiracies to Inflate Prices and Limit Competition - chadronradio.com
Maryland Announces $17.85 Million Settlement in Drug Pricing Case - The MoCo Show -
Maryland Attorney General announces $17.85 million settlements with generic drug manufacturers - nottinghammd.com
Analyst Downgrade: Is now the right time to enter ADNT2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention - Finviz
Bausch Health Companies Inc. (BHC): Investor Outlook With A 28.97% Potential Upside - DirectorsTalk Interviews
AG Jennings Secures $17.85-million Settlement with Lannett and Bausch; Compensation Possible - WGMD
Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; Sues Novartis and Sandoz - NCDOJ (.gov)
How to get compensation after DC, Md. and Va. settle $17.85M drug price fixing lawsuit - WJLA
South Dakota settles with two generic drug companies; Joins lawsuit against a third - DRGNews
Attorneys general across the U.S, including Illinois, reach nearly $18 million drug settlement - cbsnews.com
Lannett and Bausch reach $18M drug price-fixing settlement with states - Crain's New York Business
Colorado and coalition strike a deal with drug companies accused of price-fixing - Colorado Public Radio
Arizona AG announces settlements over generic drug prices - KTAR News 92.3 FM
South Dakota joins settlements totaling $17.85 million over generic drug price fixing - KOTA Territory News
AG Sunday Announces $17.85M National Settlement Over Generic Drug Price-Fixing; Pennsylvanians are Eligible for Compensation - attorneygeneral.gov
Lannett and Bausch Drug Price Fixing Deal Reaches $17.85M Multistate Settlement - USA Herald
South Dakota Attorney General Jackley Announces Settlement With Two Generic Drug Companies - South Dakota State News (.gov)
Bausch, Lannett To Pay $17.9M In Drug Price-Fixing Deal - Law360
Attorney General Tong Announces Settlements With Lannett and Bausch - CT.GOV-Connecticut's Official State Website (.gov)
Has The Market Gone Too Far In Marking Down Bausch Health (BHC) Shares? - Yahoo Finance
Bausch Health Trial Miss Puts Liver Program And Valuation In Focus - Yahoo Finance
Phase 3 RED-C Miss for Hepatic Encephalopathy Prevention Might Change The Case For Investing In Bausch Health Companies (BHC) - simplywall.st
Institutional Investors May Adopt Severe Steps After Bausch Health Companies Inc.'s (NYSE:BHC) Latest 15% Drop Adds to a Year Losses - 富途牛牛
Earnings Beat: How do insiders feel about Central Plains Bancshares IncPortfolio Performance Summary & Growth Focused Entry Reports - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Revolution Medicines (RVMD) and Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health Companies Inc. (BHC) Stock Analysis: Exploring A 28% Potential Upside - DirectorsTalk Interviews
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):